Nurix Therapeutics (NRIX) Current Deferred Revenue (2019 - 2025)
Historic Current Deferred Revenue for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $17.6 million.
- Nurix Therapeutics' Current Deferred Revenue fell 5417.58% to $17.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was $17.6 million, marking a year-over-year decrease of 5417.58%. This contributed to the annual value of $17.6 million for FY2025, which is 5417.58% down from last year.
- According to the latest figures from Q4 2025, Nurix Therapeutics' Current Deferred Revenue is $17.6 million, which was down 5417.58% from $26.0 million recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' Current Deferred Revenue registered a high of $48.1 million during Q4 2023, and its lowest value of $17.6 million during Q4 2025.
- Moreover, its 5-year median value for Current Deferred Revenue was $38.0 million (2022), whereas its average is $37.2 million.
- In the last 5 years, Nurix Therapeutics' Current Deferred Revenue surged by 4981.74% in 2024 and then crashed by 5417.58% in 2025.
- Nurix Therapeutics' Current Deferred Revenue (Quarter) stood at $41.2 million in 2021, then fell by 8.68% to $37.6 million in 2022, then increased by 27.81% to $48.1 million in 2023, then dropped by 20.24% to $38.4 million in 2024, then crashed by 54.18% to $17.6 million in 2025.
- Its Current Deferred Revenue was $17.6 million in Q4 2025, compared to $26.0 million in Q3 2025 and $27.4 million in Q2 2025.